Floatz logo

79 assets in Ovarian Neoplasm

Therapeutic assets addressing Ovarian Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Ovarian Neoplasm
GlaxoSmithKlineP4BBB (74)
Carboplatin
Ovarian Neoplasm
Eli Lilly and CompanyP3BB (71)
Docetaxel
Ovarian Neoplasm
Merck Sharp & Dohme LLCP2BB (66)
Niraparib
Ovarian Neoplasm
GlaxoSmithKlineP4BB (66)
Nogitecan
Ovarian Neoplasm
GlaxoSmithKlineP3B (63)
Cis-Diamminedichloroplatinum Ii
Ovarian Neoplasm
Merck Sharp & Dohme LLCP3B (62)
Cyclophosphamide
Ovarian Neoplasm
GlaxoSmithKlineP3B (62)
Dexasone
Ovarian Neoplasm
Zhejiang UniversityP3B (62)
Olaparib
Ovarian Neoplasm
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityP2B (62)
Etoposide
Ovarian Neoplasm
Fujian Cancer HospitalP3B (61)
Pembrolizumab
Ovarian Neoplasm
GlaxoSmithKlineP3B (61)
(R)-(1-(4-Fluorophenyl)-6-((1-Methyl-1H-Pyrazol-4-Yl)Sulfonyl)-1,4,5,6,7,8-Hexahydro-4Ah-Pyrazolo(3,4-G)Isoquinolin-4A-Yl)(4-(Trifluoromethyl)Pyridin-2-Yl)Methanone
Ovarian Neoplasm
Corcept TherapeuticsP3B (60)
Dostarlimab
Ovarian Neoplasm
Yonsei UniversityP3B (58)
Fluorouracilum
Ovarian Neoplasm
Merck Sharp & Dohme LLCP2B (58)
Eribulin/Farletuzumab Antibody Drug Conjugate
Ovarian Neoplasm
Bristol-Myers SquibbP2B (57)
Trastuzumab
Ovarian Neoplasm
Cancer Research UKP2/3B (57)
Oregovamab
Ovarian Neoplasm
CanariaBio Inc.P3B (56)
Oxaliplatin
Ovarian Neoplasm
Merck Sharp & Dohme LLCP2CCC (55)
Bleomycin
Ovarian Neoplasm
Beihua KongP3CCC (54)
Capecitabine
Ovarian Neoplasm
Merck Sharp & Dohme LLCP2CCC (54)
Lenvatinib
Ovarian Neoplasm
Merck Sharp & Dohme LLCP2CCC (54)
Mirvetuximab Soravtansine
Ovarian Neoplasm
Eli Lilly and CompanyP3CCC (54)
Nilotinib
Ovarian Neoplasm
National Cancer Institute (NCI)P2CCC (54)
Pembrolizumab/Vibostolimab Coformulation
Ovarian Neoplasm
Merck Sharp & Dohme LLCP2CCC (54)
Sacituzumab Tirumotecan
Ovarian Neoplasm
Merck Sharp & Dohme LLCP3CCC (54)
Sofetabart Mipitecan
Ovarian Neoplasm
Eli Lilly and CompanyP3CCC (54)
Tart Cherry
Ovarian Neoplasm
University of California, DavisP2CCC (53)
Cobimetinib
Ovarian Neoplasm
Cancer Research UKP2/3CCC (52)
Dabrafenib
Ovarian Neoplasm
Cancer Research UKP2/3CCC (52)
Mocertatug Rezetecan
Ovarian Neoplasm
GlaxoSmithKlineP3CCC (52)
Pertuzumab
Ovarian Neoplasm
Cancer Research UKP2/3CCC (52)
Trametinib
Ovarian Neoplasm
Cancer Research UKP2/3CCC (52)
Adebrelimab
Ovarian Neoplasm
Fujian Cancer HospitalP2CCC (51)
Catequentinib
Ovarian Neoplasm
Wenjun ChengP2CCC (51)
Disitamab Vedotin
Ovarian Neoplasm
Seagen, a wholly owned subsidiary of PfizerP2CCC (51)
Fuzuloparib
Ovarian Neoplasm
Fujian Cancer HospitalP2CCC (51)
Vemurafenib
Ovarian Neoplasm
Cancer Research UKP2/3CCC (51)
Zanidatamab
Ovarian Neoplasm
Haihua YuanP2CCC (51)
Gemogenovatucel-T
Ovarian Neoplasm
Gradalis, Inc.P2CCC (50)
Fludarabine
Ovarian Neoplasm
National Cancer Institute (NCI)P1/2CCC (48)
Neoantigen Specific Tcr-T Cell Drug Product
Ovarian Neoplasm
Alaunos TherapeuticsP1/2CCC (48)
Zelenectide Pavedotin
Ovarian Neoplasm
BicycleTx LimitedP1/2CCC (48)
a2b543
Ovarian Neoplasm
A2 Biotherapeutics Inc.P1/2CC (43)
a2b694
Ovarian Neoplasm
A2 Biotherapeutics Inc.P1/2CC (43)
Bms-936558-01
Ovarian Neoplasm
Bristol-Myers SquibbP1/2CC (43)
Bmx-001 Free Base
Ovarian Neoplasm
BioMimetix JV, LLCP1/2CC (43)
Cetuximab
Ovarian Neoplasm
Eli Lilly and CompanyP1/2CC (43)
Enzalutamide
Ovarian Neoplasm
Nuvation Bio Inc.P1CC (43)
ic9-car.b7-h3 t cells
Ovarian Neoplasm
UNC Lineberger Comprehensive Cancer CenterP1CC (43)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Cc Chemokine Receptor Ccr8) (Human-Mus Musculus Monoclonal Bms-986340 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Bms-986340 ?-Chain, Dimer
Ovarian Neoplasm
Bristol-Myers SquibbP1/2CC (43)
Showing 1 to 50 of 79 assets
PreviousPage 1 of 2Next